Among women with HER-2-positive early breast cancer, concurrent or sequential use of trastuzumab with, or after, adjuvant chemotherapy significantly improves both disease-free survival and overall survival rates [5-7]. This evidence concerns the gene ERBB2 and breast carcinoma.